News
The renewed strength in TAVR, following a slowdown last year tied to heart team capacity challenges at hospitals, prompted ...
Zacks Investment Research on MSN2d
EW Stock Climbs on Q2 Earnings & Revenue Beat, Margins Down
Edwards Lifesciences Corporation EW reported second-quarter 2025 adjusted earnings per share (EPS) of 67 cents, which ...
Edwards Lifesciences has lifted its 2025 profit outlook to between 9%-10%, up from 8%-10%, amid strong Q2 2025 performance in its Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral ...
Background Current risk scores inadequately predict long-term mortality after transcatheter aortic valve replacement (TAVR), limiting their ability to guide decisions around procedural futility. We ...
Investor's Business Daily on MSN2d
How Boston Scientific's Loss Was Edwards Lifesciences' Gain In the Second Quarter
Edwards Lifesciences stock surged late Thursday after the medtech hiked its outlook following a key setback for rival Boston ...
Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2025. Recent Highlights. Q2 sales g ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback